Dovetail Genomics, Illumina Collaborate
News Sep 15, 2016
Dovetail GenomicsTM LLC has announced that it has signed a co-marketing agreement with Illumina for the promotion of Dovetail’s genome sequencing and assembly services for long-range sequencing applications leveraging Illumina sequencing technology. Dovetail’s in vitro proximity ligation-based ChicagoTM libraries, prepared for Illumina platforms, generate read-pairs that span genome distances up to the maximum size of the input DNA.
Using the Chicago data and a draft assembly, the company’s HiRiseTM software pipeline identifies and breaks misjoins in the draft assembly and then iteratively joins contigs and scaffolds into a final assembly, resulting in as much as 200x improvement in scaffold contiguity. “Illumina’s accurate, high-throughput sequencing solutions coupled with Dovetail’s proprietary Chicago libraries are providing our customers with a powerful and affordable long-range genome assembly solution,” said Todd Dickinson, Dovetail Genomics’ Chief Executive Officer.
“Since launching our services in October of last year, we have produced assemblies for more than 100 different organisms, driving increased access to and use of reference-quality genomes. We are thrilled to partner more closely with Illumina to further expand our market reach as we continue to grow our business.”
“Our new co-marketing relationship with Dovetail Genomics enables us to continue growing the
ecosystem around Illumina’s powerful sequencing technology for long-read applications,” said Christian Henry, Illumina’s Executive Vice President and Chief Commercial Officer.
“Dovetail offers a proven research use only solution for long-range sequencing. Their assembly services produce accurate and highly-contiguous genome assemblies, meeting an essential requirement for many of our customers.” The two companies will begin co-marketing the Dovetail genome assembly service immediately.
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE
Getting to Know the Microbes that Drive Climate ChangeNews
A new understanding of the microbes and viruses in the thawing permafrost in Sweden may help scientists better predict the pace of climate change.READ MORE